Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.

Pfizer's innovative business should grow faster after it divests its off-patent division Upjohn in 2020 to create Viatris and Mylan. With fewer older medications and fewer patent losses, Pfizer is ...

Pfizer’s Debt figure was $61 Bil at the end of the most recent quarter, while its market capitalization is $133 Bil (as of 6/2/2025). This implies a poor Debt-to-Equity Ratio of 46.2% (vs. 19.9% ...

A second ultra-high-yield dividend stock that makes for a no-brainer buy in June is none other than pharmaceutical giant Pfizer (PFE 0.40%), which is yielding north of 7.3% for its shareholders.

Jim Cramer recently endorsed Pfizer, excited by its cancer-fighting potential and robust drug pipeline. A caller praised Pfizer’s phase three drugs and its new Chinese biotech deal, which Cramer ...

Pfizer Inc. announced statistically significant and clinically meaningful survival results from the phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Offi ...

Pfizer upped the ante last month by paying 3SBio $1.25 billion upfront for a PD-1xVEGF bispecific that is set to enter phase 3 in China this year. BMS has been keeping tabs on the space, ...

About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive ...

Recent research has linked Pfizer's widely-used Depo-Provera birth control shot to massively increased risk of developing brain tumors — and hundreds of women are suing the pharmaceutical giant ...